In This Article:
On Friday, QIAGEN N.V. QGEN reached a milestone with more than 1000 EZ2 Connect automated sample preparation instrument placements. The updated EZ2 Connect has quickly become a market-leading instrument for sample preparation and data management, contributing to over 5,500 EZ series instruments placed globally.
The latest development highlights customers’ trust in QIAGEN’s automation portfolio to enhance laboratory operations.
QGEN Stock’s Trend Following the News
Subsequent to the news, QGEN's share price moved south 0.02% to $43.42 on Friday. QIAGEN is gaining synergies from its continuous efforts in expanding its portfolio of automated sample preparation solutions, aiming to support laboratories in achieving greater efficiency and consistency in their processes. Henceforth, we expect the latest achievement to motivate market sentiment in favor of QGEN in the upcoming days.
QIAGEN currently has a market capitalization of $9.65 billion. The company delivered an average earnings surprise of 3.52% for the trailing four quarters.
About QIAGEN’s EZ2 Connect
Launched in 2021, EZ2 Connect automates the entire nucleic acid purification process, reducing hands-on time and increasing throughput while maintaining high precision and reproducibility. Using EZ2 Connect enables researchers to focus on data analysis and interpretation instead of repetitive manual sample processing. The system is particularly beneficial for laboratories handling medium volumes of samples for use across a range of downstream molecular biology research applications, such as digital PCR and next-generation sequencing (NGS).
The EZ2 Connect portfolio encompasses kits and instruments such as EZ2 Connect MDx tailored for diagnostic applications and clinical labs, and EZ2 Connect FX supporting forensic scientists with dedicated human ID and forensics protocols.
QIAGEN’s Business Advancements
QIAGEN has recently launched the EZ2 PowerFecal Pro DNA/RNA Kit. The new kit expands the EZ2 Connect consumables portfolio into gut microbiome research. With this, researchers can learn about gut bacteria's role in metabolic processes, immune function and disease progression.
The company plans to expand the EZ2 Connect portfolio by introducing new kits in 2025 for the isolation of RNA from blood samples and forensic applications.
Industry Prospects Favor QIAGEN
Per a Bis Research report, the global automated sample preparation market was valued at $1.43 billion in 2023 and is expected to reach $3.73 billion by 2033 at a compound annual growth rate of 10% during the period. The market’s growth is driven by the increasing demand for high-throughput and standardized sample processing, especially in industries such as genomics. Additionally, the rising prevalence of infectious diseases and cancer cases also fuels market growth.